ReviewInternational journal of environmental research and public health2022
Non-Epithelial Ovarian Cancers: How Much Do We Really Know?
Review in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Metabolic syndrome and risk of ovarian cancer: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.Journal of ovarian research · 2022Pooled it
- Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Trial
- Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Trial
- Article
- Prevalence and Management of Nonepithelial Ovarian Cancer in a Sub-Saharan African Setting.Obstetrics and gynecology international · 2026Article
- From Inflammation to Malignancy: The Link Between Endometriosis and Gynecological Cancers.International journal of molecular sciences · 2025Review
- Laparoscopy in the Surgical Management of Gynecological Cancer: A Comprehensive Update.Journal of clinical medicine · 2025Review
- Article
- Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.British journal of cancer · 2025Article
- Malignant germ cells tumor of the ovary.Journal of gynecologic oncology · 2025Review
- Article
- Steroid metabolism and hormonal dynamics in normal and malignant ovaries.Essays in biochemistry · 2024Review
- Risk Factors for Ovarian Cancer in South America: A Literature Review.Journal of personalized medicine · 2024Review
- Single-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma.Journal of Zhejiang University. Science. B · 2024Article
- Real Implication of Fertility-Sparing Surgery for Ovarian Cancer: Reproductive Outcomes.Diagnostics (Basel, Switzerland) · 2024Article
- miR‑146a‑5p and miR‑191‑5p as novel diagnostic marker candidates for ovarian clear cell carcinoma.Molecular and clinical oncology · 2024Article
- Giant ovarian yolk sac tumor during late pregnancy: a case report and literature review.Frontiers in oncology · 2024Article
- Overview of Molecular Diagnostics in Irish Clinical Oncology.HRB open research · 2024Article
- Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.Therapeutic advances in medical oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-epithelial ovarian cancers (NEOC) are a group of uncommon malignancies that mainly includes germ cell tumours (GCT), sex cord-stromal tumours (SCST), and some extremely rare tumours, such as small cell carcinomas and sarcomas. Each of these classifications encompasses multiple histologic subtypes. The aetiology and molecular origins of each sub-group of NEOC require further investigation, and our understanding on the genetic changes should be optimised. In this article, we provide an update on the clinical presentation, pathology, genetics, treatment and survival of the main histological subtypes of the GCT and the SCST, as well as of ovarian small cell carcinomas. We also discuss miRNA expression profiles of NEOC and report the currently active clinical trials that include NEOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.